Shelter Mutual Insurance Co lessened its stake in Abbott Laboratories (NYSE:ABT) by 8.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 93,300 shares of the healthcare product maker’s stock after selling 8,800 shares during the quarter. Shelter Mutual Insurance Co’s holdings in Abbott Laboratories were worth $4,978,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Capital Research Global Investors boosted its stake in Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after acquiring an additional 14,918,038 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Abbott Laboratories by 3,373.9% during the 2nd quarter. Janus Henderson Group PLC now owns 7,874,473 shares of the healthcare product maker’s stock worth $382,779,000 after acquiring an additional 7,647,798 shares during the last quarter. Vanguard Group Inc. boosted its stake in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock worth $6,308,944,000 after acquiring an additional 3,241,063 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Abbott Laboratories by 28.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock worth $569,830,000 after acquiring an additional 2,606,404 shares during the last quarter. Finally, Boston Partners boosted its stake in Abbott Laboratories by 28.1% during the 2nd quarter. Boston Partners now owns 10,516,502 shares of the healthcare product maker’s stock worth $511,207,000 after acquiring an additional 2,304,467 shares during the last quarter. Hedge funds and other institutional investors own 71.15% of the company’s stock.

Several research firms recently weighed in on ABT. Barclays reissued a “buy” rating and set a $66.00 price objective on shares of Abbott Laboratories in a research note on Monday. BMO Capital Markets reissued a “market perform” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Bank of America reissued a “buy” rating and set a $60.00 price objective (up previously from $56.00) on shares of Abbott Laboratories in a research note on Wednesday, October 4th. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Morgan Stanley raised shares of Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 price objective on the stock in a research note on Tuesday, January 2nd. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $59.94.

In other news, Chairman Miles D. White sold 276,886 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the sale, the chairman now directly owns 3,677,913 shares in the company, valued at $200,115,246.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sharon J. Bracken sold 2,188 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $56.12, for a total transaction of $122,790.56. Following the completion of the sale, the insider now owns 25,618 shares in the company, valued at $1,437,682.16. The disclosure for this sale can be found here. Insiders sold 501,172 shares of company stock worth $27,533,150 over the last quarter. 0.76% of the stock is owned by corporate insiders.

Shares of Abbott Laboratories (NYSE ABT) opened at $58.82 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The company has a market cap of $102,380.00, a P/E ratio of 48.61, a price-to-earnings-growth ratio of 1.88 and a beta of 1.55. Abbott Laboratories has a fifty-two week low of $39.25 and a fifty-two week high of $59.60.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. During the same period last year, the company posted $0.59 EPS. The business’s quarterly revenue was up 28.8% on a year-over-year basis. equities analysts anticipate that Abbott Laboratories will post 2.5 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a $0.28 dividend. The ex-dividend date is Thursday, January 11th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.90%. Abbott Laboratories’s dividend payout ratio (DPR) is 87.60%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/shelter-mutual-insurance-co-lowers-holdings-in-abbott-laboratories-abt/1799301.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.